This formed the basis for selecting pembrolizumab as the neoadjuvant immunotherapy agent in the current patient, with the patient having known Lynch syndrome and immunohistochemical analysis of the tumour biopsy confirming deficiencies in MLH1 and PMS2. This evidence concerns the gene PMS2 and neoplasm.